Home/Pipeline/VK2735 (Subcutaneous)

VK2735 (Subcutaneous)

Obesity

Phase 3Active - Enrollment Complete for VANQUISH-2

Key Facts

Indication

Obesity

Phase

Phase 3

Status

Active - Enrollment Complete for VANQUISH-2

Company

Viking Therapeutics

About Viking Therapeutics

Viking Therapeutics is a US-based, publicly-traded biotech focused on developing innovative small-molecule drugs for metabolic diseases. Its core achievement is advancing VK2735, a dual GLP-1/GIP agonist, into a Phase 3 obesity program with both subcutaneous and oral formulations, demonstrating significant weight loss in mid-stage trials. The company's strategy leverages deep expertise in hormone receptor pharmacology to create differentiated therapies with potential advantages over existing incretin-based treatments. With a market cap of approximately $3.63 billion, Viking has captured substantial investor interest as a key player in the next generation of obesity therapeutics.

View full company profile

Therapeutic Areas

Metabolic Disorders Endocrine Disorders Obesity

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active